Bio-Rad Laboratories, Inc. $BIO Shares Bought by GW&K Investment Management LLC

GW&K Investment Management LLC raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 24.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 183,845 shares of the medical research company’s stock after purchasing an additional 36,632 shares during the period. GW&K Investment Management LLC owned 0.68% of Bio-Rad Laboratories worth $51,550,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. First Eagle Investment Management LLC raised its position in shares of Bio-Rad Laboratories by 60.7% during the 2nd quarter. First Eagle Investment Management LLC now owns 2,517,313 shares of the medical research company’s stock worth $607,478,000 after purchasing an additional 951,123 shares during the last quarter. Norges Bank acquired a new stake in Bio-Rad Laboratories during the 2nd quarter valued at $30,987,000. Ilex Capital Partners UK LLP increased its position in Bio-Rad Laboratories by 1,790.3% during the second quarter. Ilex Capital Partners UK LLP now owns 120,885 shares of the medical research company’s stock worth $29,172,000 after buying an additional 114,490 shares in the last quarter. Boston Trust Walden Corp acquired a new position in shares of Bio-Rad Laboratories in the third quarter worth $26,763,000. Finally, Scopia Capital Management LP purchased a new stake in shares of Bio-Rad Laboratories in the second quarter valued at $22,862,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

More Bio-Rad Laboratories News

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Zacks raised its Q1 2027 EPS forecast to $2.22 (from $2.12), a modest upward revision that could be read as a small near-term beat to expectations for that quarter.
• Neutral Sentiment: Zacks published an initial FY2028 EPS estimate of $9.87. As an early/forward-year projection this is informative but carries uncertainty and is not directly comparable to current-year consensus figures.
• Negative Sentiment: Zacks cut a string of near‑ and medium‑term EPS forecasts — small trims to Q1 2026 ($2.77), Q2 2026 ($2.34), Q4 2026 ($2.59) and FY2026 (to $10.32 from $10.36), and larger cuts to FY2027 (to $9.30 from $9.38) and several Q2–Q3 2027 quarters — signaling a weaker earnings trajectory than previously modeled. These downward revisions, taken together, are the main negative catalyst from this batch of research notes because they lower forward earnings expectations and could pressure valuation multiples.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BIO. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $358.50.

Bio-Rad Laboratories Price Performance

BIO stock opened at $284.83 on Thursday. The stock has a market capitalization of $7.69 billion, a price-to-earnings ratio of 10.21 and a beta of 1.18. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $343.12. The stock’s fifty day simple moving average is $296.91 and its 200-day simple moving average is $301.34.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $2.57 by ($0.06). Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The business had revenue of $693.20 million for the quarter, compared to analysts’ expectations of $694.64 million. During the same quarter last year, the company posted $2.90 earnings per share. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. Equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.